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Expression and activity of soluble guanylate cyclase in injury
and repair of anti-thy1 glomerulonephritis.
Background. Activation of soluble guanylate cyclase and
generation of cyclic 3′,5′-guanosine monophosphate (cGMP) is
the main signal transducing event of the L-arginine-nitric oxide
pathway. The present study analyzes the expression and activity
of the nitric oxide-cGMP signaling cascade in and the effect of
the specific soluble guanylate cyclase stimulator Bay 41-2272 on
the early injury and subsequent repair phase of acute anti-thy1
glomerulonephritis.
Methods. Anti-thy1 glomerulonephritis was induced by OX-
7 antibody injection in rats. In protocol 1 (injury), Bay 41-
2272 was given starting 6 days before antibody injection.
One day after disease induction, parameters of mesangial cell
injury (glomerular cell number and inducible nitric oxide syn-
thesis) were analyzed. In protocol 2 (repair), Bay 41-2272 treat-
ment was started one day after antibody injection. On day 7,
parameters of glomerular repair [glomerular matrix score, ex-
pression of transforming growth factor (TGF)-b1, fibronectin,
and plasminogen-activator-inhibitor (PAI)-1, infiltration with
macrophages and fibrinogen deposition (indicating platelet lo-
calization)] were determined. In both protocols, tail bleeding
time, systolic blood pressure, plasma cGMP levels, glomerular
mRNA expression of endothelial nitric oxide synthase (eNOS),
a1 and b1 soluble guanylate cyclase, and basal and nitric oxide-
stimulated glomerular cGMP production were analyzed.
Results. Bay 41-2272 prolonged bleeding time, reduced blood
pressure, and increased plasma cGMP levels in both proto-
cols. In the injury experiment, disease induction increased
inducible nitric oxide synthesis and reduced glomerular cell
number, while expression and activity of soluble guanylate cy-
clase was almost completely diminished. Bay 41-2272 did not
affect parameters of mesangial cell injury and glomerular sol-
uble guanylate cyclase expression and activity. In the repair
protocol, expression and activity of soluble guanylate cyclase
was markedly increased by disease. Bay 41-2272 further en-
hanced soluble guanylate cyclase expression and activity. This
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went along with significant reductions in proteinuria, glomeru-
lar matrix accumulation, expression of TGF-b1, fibronectin,
and PAI-1, macrophage infiltration and fibrinogen deposition
as compared to the untreated anti-thy1 animals.
Conclusion. Glomerular nitric oxide signaling via cGMP is
markedly impaired during injury of anti-thy1 glomerulonephri-
tis, while it is highly up-regulated during subsequent repair.
Further pharmacologic soluble guanylate cyclase stimulation
limits glomerular TGF-b overexpression and matrix expan-
sion, suggesting that the soluble guanylate cyclase enzyme
represents an important antifibrotic pathway in glomerular
disease.
Nitric oxide is endogenously generated from the
amino acid L-arginine and is a key messenger and ef-
fect molecule in a wide variety of mammalian functions
ranging from vasodilatation and platelet disaggrega-
tion to neuronal transmission and immune defense [1].
The intracellularly located enzyme soluble guanylate
cyclase [guanosine triphosphate (GTP) pyrophosphate-
lyase (cycling) EC 4.6.1.2] is the principal physiologic tar-
get for the freely diffusible molecule nitric oxide and rep-
resents its main signaling pathway via generation of cyclic
3′,5′-guanosine monophosphate (cGMP) [2, 3]. Soluble
guanylate cyclase is a heterodimeric enzyme that is ex-
pressed predominately as a1b1 heterodimer in various
tissues, including the kidney [3, 4]. Within the soluble
guanylate cyclase, nitric oxide binds to a haem prosthetic
group that is linked to the His-105 residue of the b sub-
unit. This binding is thought to lead to a transformational
protein conformation and to a subsequent activation of
the enzyme with a several hundredfold increase in cGMP
generation [3]. cGMP is the second messenger molecule
of the L-arginine-nitric oxide pathway and regulates fur-
ther downstream effector mechanisms such as cGMP-
dependent protein kinases, cGMP-gated ion channels
and cGMP-regulated phosphodiesterases to finally pro-
duce nitric oxide’s main biologic effects [5].
Research over the last decade has shown that the
L-arginine-nitric oxide pathway is critically involved in
pathologic matrix production and accumulation of the
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kidney [6–10]. Using L-arginine administration to acti-
vate the L-arginine-nitric oxide pathway, previous studies
have documented both beneficial and detrimental out-
comes. In the rat model of anti-thy1-antibody–induced
glomerulonephritis, L-arginine supplementation has been
reported to limit glomerular overexpression of the key fi-
brosis mediator transforming growth factor (TGF)-b and
matrix accumulation during its repair phase [11]. In a sub-
sequent study using the same model, we have recently
shown that this beneficial effect of L-arginine is mainly
mediated via endogenous generation of nitric oxide and
can be mimicked by pharmacologic nitric oxide dona-
tion [12]. However, in these studies it remained unclear,
whether the protective, antifibrotic effect of nitric oxide
is transduced by cGMP, and whether nitric oxide signal-
ing via cGMP is affected during the course of anti-thy1
glomerulonephritis.
The present study was designed to characterize the role
of the nitric oxide-cGMP signaling cascade during the
course of anti-thy1 antibody-induced glomerulonephri-
tis. In two separate protocols, the expression and activity
of the nitric oxide-cGMP signaling cascade was analyzed
during the early injury (day 1 after antibody injection)
and the subsequent repair phase (day 7 after antibody
injection). The early injury phase in anti-thy1 glomeru-
lonephritis is characterized by an anti-thy1 antibody- and
nitric oxide-dependent lysis of the mesangial cells [13].
The subsequent repair phase shows a rapid and marked
glomerular TGF-b overexpression and matrix protein ex-
pansion [10]. To further characterize the role of nitric
oxide-cGMP signaling in glomerular injury and repair,
the novel, orally applicable compound Bay 41-2272 was
given to nephritic animals in order to specifically enhance
the activity of soluble guanylate cyclase [14]. Bay 41-2272
is a pyrazolopyridine derivate that amplifies cGMP gener-
ation specifically and multifoldly in the presence of given,
physiologic or low nitric oxide concentrations, through in-
teraction with the soluble guanylate cyclase enzyme. In
addition, Bay 41-2272 is also capable of an nitric oxide-
independent stimulation of the soluble guanylate cyclase.
METHODS
Materials
Unless otherwise indicated, materials, chemicals or
culture media were purchased from Sigma Chemical-
Aldrich Co. (Taufkirchen, Germany).
Animals
Male Wistar rats (180 to 250 g) were obtained from
Charles River (Sulzfeld, Germany) and fed a normal pro-
tein diet (22.5% protein) (Altromin, Lage, Germany) for
at least 3 days before the start of the experiment to allow
equilibration. Body weight was determined at the begin-
ning and end of each experiment. Animals were housed
in a constant temperature room with a 12-hour dark/12-
hour light cycle. Food and water intakes were monitored.
Animal care and treatment were in conformity with the
guidelines of the American Physiological Society and ap-
proved by local authorities.
Induction of acute anti-thy1 glomerulonephritis
Acute anti-thy1 glomerulonephritis was induced by tail
vein injection of the monoclonal antibody OX-7 [1 mg/kg
body weight in phosphate-buffered saline (PBS)] as pre-
viously described [12]. In the kidney, OX-7 binds to a
thy1-like antigen on the surface of mesangial cells and
causes complement- and nitric oxide-dependent mesan-
gial cell lysis [13]. Control animals were injected with
equal volumes of PBS only. OX-7 antibody was produced
from a hybridoma cell line as previously described [12].
The antibody were diluted in PBS (pH 7.4) and stored at
–70◦C until use.
Drug administration
Chemically, Bay 41-2272 is 5-cyclopropyl-2-[1-(2-flu-
oro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-
4-ylamine. It belongs to a new class of drugs that
markedly amplify the cGMP output of soluble guanylate
cyclase in the presence of given amounts of nitric oxide
[14]. In addition, Bay 41-2272 also has the ability to
directly stimulate soluble guanylate cyclase activity in
the absence of nitric oxide. This novel class of drugs has
been designated as soluble guanylate cyclase enhancers
or soluble guanylate cyclase stimulators. Bay 41-2272 is
structurally related to YC-1, the first member of the class
of soluble guanylate cyclase enhancers [3]. However,
in contrast to YC-1, Bay 41-4272 is orally applicable
and does not inhibit the activity of the cGMP-degrading
phosphodiesterase-5 [3, 14]. Photoaffinity studies have
suggested that the cysteine 238 or 243 region of the a1
subunit of the soluble guanylate cyclase is target of Bay
41-2272. Bay 41-2272 has recently been shown to reduce
the platelet activity in vitro, to decrease blood pressure,
and to prolong survival in a high-renin, low nitric oxide
model of hypertension [i.e., L-nitro-arginine methyl
ester (L-NAME)-treated transgenic renin rats [14]].
In our experiments, Bay 41-2272 was given with the
food in a dose of 10 mg/kg body weight/day. This dose
has previously been reported to reduce sufficiently the
mean arterial blood pressure in spontaneously hyperten-
sive rats [14]. Bay 41-2272 was generously provided by Dr.
Johannes-Peter Stasch, Pharma Research Center, Bayer
AG, Wuppertal, Germany. The drug-containing food was
produced in our laboratory by using the flour of the
standard rat chow (22.5% protein, A1311) (Altromin) as
previously described [15]. Briefly, Bay 41-2272 was mixed
into the dry food flour in appropriate amounts, water was
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added to form pellets, and the air-dried pellets were sub-
sequently given to the animals.
Experimental design
The expression and activity of the nitric oxide-cGMP
pathway was separately analyzed in the early injury
phase (protocol 1) and the subsequent matrix expansion
phase of acute anti-thy1 glomerulonephritis. The expres-
sion analysis of the nitric oxide-cGMP cascade included
mRNA expression of endothelial nitric oxide synthase
(eNOS) and a1 and b1 soluble guanylate cyclase. The ac-
tivity of glomerular soluble guanylate cyclase was deter-
mined at basal level and in response to a defined amount
of nitric oxide in freshly-isolated glomeruli ex vivo. In the
injury experiment, glomerular cell number and inducible
nitric oxide production were analyzed as indicators of
mesangial cell injury. In the repair protocol, parameters
of glomerular matrix expansion (glomerular matrix score
and expression of TGF-b1, fibronectin, and plasmino-
gen activator inhibitor type 1 [PAI-1] protein) were mea-
sured. In both protocols, an additional group of nephritic
animals was treated with the soluble guanylate cyclase en-
hancer Bay 41-2272. In protocol 1 (injury), Bay 41-2272
treatment started 6 days before and continued until 24
hours after injection of anti-thy1-antibody. In protocol 2
(repair), Bay 41-2272 treatment started 1 day after and
continued until day 7 after antibody administration.
Soluble guanylate cyclase in the injury phase of acute
anti-thy1 glomerulonephritis (day 1 after antibody
injection) (protocol 1)
Six days before antibody injection, Wistar rats were
assigned to the following groups: (1) PBS-injected con-
trols (N = 6); (2) anti-thy1 antibody-injected rats, no
treatment (glomerulonephritis) (N = 10); and (3) anti-
thy1 antibody-injected rats plus Bay 41-2272 (glomeru-
lonephritis + Bay 41-2272) (N = 10).
One day after antibody injection, the histological de-
gree of mesangial cell lysis and the release of basal and
lipopolysaccharide (LPS)-stimulated nitrite of cultured
glomeruli were analyzed. At this point, mesangial cell
lysis is complete and inducible glomerular nitric oxide
production is markedly increased [16].
Soluble guanylate cyclase in the repair phase
of anti-thy1 glomerulonephritis (day 7 after
antibody injection) (protocol 2)
One day after antibody injection, when the mesan-
gial cell lysis had occurred and the fibrotic response had
started [16], Wistar rats were assigned to the following
groups: (1) PBS-injected controls (N = 6); (2) anti-thy1
antibody-injected animals, no treatment (glomeru-
lonephritis) (N = 10); and (3) anti-thy1 antibody-injected
rats plus Bay 41-2272 (glomerulonephritis + Bay 41-
2272) (N = 12).
Seven days after disease induction, expression of the
key fibrosis mediator and marker TGF-b served as the
principal therapeutic target. To document that TGF-b
expression reflected actual matrix accumulation, a histo-
logic glomerular matrix score was used. In addition, renal
expression of the matrix protein fibronectin was mea-
sured as an indicator for matrix protein production. The
protease inhibitor PAI-1 was used as sensitive marker of
the matrix degrading system. In acute anti-thy1 glomeru-
lonephritis, the fibrotic response peaks 7 days after anti-
body injection [12]. In order to further elucidate mech-
anisms underlying potentially a beneficial effect of Bay
41-2272 on glomerular matrix expansion, its effects on
glomerular macrophage infiltration and intraglomeru-
lar thrombosis in vivo as well as on TGF-b production
of normal and nephritic glomeruli in vitro were ana-
lyzed. Since cGMP-dependent inhibition of tissue leuko-
cytes recruitment has recently been related to a down-
regulation of the adhesion molecule p-selection [17], im-
munhistologic detection of glomerular macrophage infil-
tration was paralleled by measuring the mRNA expres-
sion of p-selectin. Intraglomerular thrombosis is com-
monly seen during the repair phase of acute anti-thy1
glomerulonephritis and indicates glomerular deposition
of platelets as platelet-fibrinogen aggregates [15]. Im-
munhistologic fibrinogen staining was used as indirect
marker for glomerular platelet deposition.
Protocols 1 and 2
Bleeding time, blood pressure, and plasma cGMP lev-
els were analyzed in the subgroups of both protocols (N =
4 to 6 per group per protocol). Since the results for the
two protocols were very similar and did not provide addi-
tional information, they are as a combination presented
in the Results section.
Bleeding time
Rat tail bleeding time was analyzed as previously re-
ported in anesthetized animals with a standardized inci-
sion (10 mm long, 1 mm deep) on the dorsal part of the
tail [15].
Urine collection and measurement of proteinuria
In protocol 2, 24-hour urine was collected from each rat
the day before sacrifice, using metabolic cages. Urinary
protein concentration was measured by a pyrogallol red
method using a microplate technique [12]. Proteinuria is
expressed as mg protein/24 hours.
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Sacrifice
At the end of each experiment, animals were anes-
thetized with ketanest (50 mg/kg body weight) (Pharma-
cia GmbH, Erlangen, Germany)/xylazin (10 mg/kg body
weight) (Bayer Vital GmbH, Leverkusen, Germany).
Following a midline abdominal incision, 5 to 10 mL
blood was drawn from the abdominal aorta into ethylene-
diaminetetraacetic acid (EDTA)-coated syringes. The
blood-filled syringes were immediately cooled on ice. In
parallel, the rat kidneys were subsequently perfused with
40 mL ice-cold PBS. For histologic examination, corti-
cal tissue was fixed in 10% neutral buffered formalin.
The cooled rat blood was subsequently centrifuged at
4◦C, and 20 lL of 5 mmol/L 3-isobutyl-1 methylxanthine
(IBMX) (Alexis GmbH, Gru¨nberg, Germany) was added
to 980 lL of plasma to block cGMP degeneration. Sam-
ples were stored at −20◦C until measurement of cGMP
concentration.
Glomerular isolation and culture
Glomeruli from individual rats were isolated by
a graded sieving technique (160, 125, and 71 lm
mesh metal sieves) as described previously [12].
Glomeruli were suspended in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 0.1 U/mL in-
sulin, 100 U/mL penicillin, and 100 lg/mL streptomycin
at a density of 2000 per mL.
Basal and nitric oxide-stimulated glomerular cGMP
production
Volumes of 150 lL of the resuspended glomeruli were
placed into the wells of a 96-well microplate and pre-
warmed at 37◦C/5% CO2. After 1 hour, 20 lL 5 mmol/L
IBMX was added to each well to block cGMP degrada-
tion. After 10 minutes of incubation at 37◦C/5% CO2, the
glomeruli were exposed to 20 lL 1 mmol/L diethylamine-
NONOate (DEA/NO), a fast nitric oxide-releasing
compound (Alexis GmbH, Gru¨nberg, Germany) and in-
cubated for another 10 minutes at 37◦C/5% CO2. To
stop the reaction, the microplate was quickly put on ice,
and 20 lL 5% dodecytrimethylammonium bromide was
added to stop the reaction and to facilitate cell lysis. Thus
results express total (intra- and extracellular) cGMP lev-
els. Lysed cells were stored at −80◦C until analysis.
Measurement of cGMP
cGMP levels in plasma and glomerular lysates
were measured by enzyme-linked immunosorbent as-
say (ELISA) (Amersham Pharmacia Biotech, Freiburg,
Germany) according to the manufacturer’s instructions.
Briefly, samples, standards and peroxidase-labeled cGMP
conjugate were transferred to a microplate precoated
with a cGMP-specific antibody. After addition of sub-
strate, optical density was read at 450 nm using an au-
tomated plate reader (MRX II) (Dynex Technologies,
Frankfurt am Main, Germany). The results are expressed
as fmol per mL for plasma and fmol cGMP per well for
glomerular lysates.
Basal and LPS-stimulated glomerular nitric oxide
production
In protocol 1 (injury), glomeruli were cultured at a
density of 2000 per mL for 48 hours (basal nitric oxide
glomerular production). Additional samples were cul-
tured in the presence of 10 lg LPS from Escherichia
coli (serotype 0127:B8) to stimulate inducible nitric ox-
ide production (stimulated glomerular nitric oxide pro-
duction). Nitrite served as indicator of nitric oxide pro-
duction and was determined by the Griess reaction in
glomerular culture supernatants [18]. Briefly, 50 lL of
sample was mixed with 100 lL Griess reagent (0.05%
N-[1-naphthyl] ethylene diamine dihydrochloride, 0.5%
sulfanilamide in 45% glacial acetic acid) in 96-well plates.
After 10 minutes of incubation in the dark, absorbance
was read at 570 nm in an automated plate reader (MRX
II) (Dynex Technologies). Standard samples were pre-
pared with sodium nitrite.
Effect of Bay 41-2272 on glomerular TGF-b1 production
in vitro
To demonstrate that stimulation of the soluble guany-
late cyclase regulates TGF-b production directly and in-
dependently of blood pressure, glomeruli from six normal
and eight nephritic rats (day 7 after OX-7 injection, pro-
tocol 2) were re-suspended in DMEM culture medium at
a density of 2000 per mL. The soluble guanylate cyclase
stimulator Bay 41-2272 was added in increasing concen-
trations: 0, 0.1, 1, 5, and 10 lmol/L. After 48 hours’ in-
cubation at 37◦C/5% CO2, supernatants were harvested
and stored at –20◦C until analysis of glomerular TGF-
b1 production. Two samples from each animal and Bay
41-2272 concentration were analyzed.
Glomerular production of TGF-b1, fibronectin,
and PAI-1
Glomeruli were cultured at a density of 2000 per mL
at 37◦C/5% CO2. After 48 hours of incubation, super-
natants were harvested and stored at −20◦C until anal-
ysis. In previous experiments, we have shown that the
TGF-b1, fibronectin, and PAI-1 production by glomeruli
ex vivo is constant over 48 hours and closely correlates to
the actual glomerular matrix accumulation in vivo [11].
TGF-b1 content of culture supernatant was measured af-
ter acid activation using a commercially available ELISA
kit (TGF-b1 DuosetTM; R&D Systems, Wiesbaden,
Germany) according to the manufacturer’s instruc-
tions. Fibronectin and PAI-1 levels were measured with
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Fig. 1. Tail bleeding time (A) and systolic
blood pressure (B) in rats with induced anti-
thy1 glomerulonephritis (GN). Shown are the
effects of the pharmacologic soluble guany-
late cyclase stimulator Bay 41-2272. Normal
control animals (control) were injected with
phosphate-buffered saline (PBS). Anti-thy1
glomerulonephritis was induced by injection
of OX-7 antibody. Bleeding was induced by a
standard tail incision (10 mm long and 1 mm
deep) in anesthetized animals. Blood pressure
was measured in conscious animals using a tail
cuff method. ∗∗P < 0.01 vs. GN.
inhibitory ELISA as previously described [12]. Three
samples from each rat were analyzed.
Glomerular mRNA expression of endothelial nitric oxide
synthase (eNOS), a1 and b1 soluble guanylate cyclase,
inducible nitric oxide synthase (iNOS), p-selectin, and
glyceraldehyde-3-phophate dehydrogenase (GAPDH)
Glomerular total RNA was extracted with TrizolTM
reagent (Gibco BRL, Berlin, Germany) according to
the manufacturer’s instructions. The mRNA expression
of iNOS, eNOS, soluble guanylate cyclase and GAPDH
were determined by a “two-step” reverse transcription-
polymerase chain reaction (RT-PCR). A cDNA copy was
created with reverse transcriptase from RNA PCR Core
kit (Roche, Applied Biosystems, Branchburg, NJ, USA).
Real-time PCR was performed using the LightCycler
System and SYBR Green I as dsDNA binding dye
(Roche Diagnostics GmbH, Mannheim, Germany).
The following primer pairs were used (annealing tem-
perature in parenthesis): eNOS sense 5′-TCCAGT
AACACAGACAGTGC-3′, antisense 5′-CAGGAAGT
AAGTGAGAGCCTG-3′ (61◦C); a1 soluble guanylate
cyclase sense 5′-CCACATCAACACAGGCTAAT-
3′, antisense 5′-GAAGTGCAAGGTTCAGTCTC-3′
(62◦C); b1 soluble guanylate cyclase sense 5′-CGGATGC
CACGGTATTGTCT-3′, antisense 5′-CTCCTGGCTT
GACGCACATT-3′ (62◦C); p-selectin sense 5′-ACCAT
GACGTGTATCCAGCC-3′, antisense 5′-CCTTCGTC
ACACATGAACTG-3′ (61◦C); GAPDH sense 5′-CCAT
CTTCCAGGAGCGAGAT-3′, antisense 5′-GATGA
CCTTGCCCACAGCCT-3′ (59◦C); and iNOS sense 5′-
GCAGAATGTGACCATCATGG-3′, antisense 5′-ACA
ACCTTGGTGTTGAAGGC-3′ (60◦C). For analysis, a
relative quantification method was used as previously
described [19, 20]. Briefly, amplification is described as
N = N0 ∗ ECP where N is the number of amplified
molecules; N0 is the initial number of molecules; E is the
amplification efficiency; and CP is the crossing point
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Fig. 2. Plasma cyclic guanosine monophosphate (cGMP) levels in rats
with induced anti-thy1 glomerulonephritis (GN). Shown are the ef-
fects of the pharmacologic soluble guanylate cyclase stimulator Bay 41-
2272. Normal control animals (control) were injected with phosphate-
buffered saline (PBS). Anti-thy1 glomerulonephritis was induced by
injection of OX-7 antibody. ∗P < 0.05 and ∗∗P < 0.01 vs. control; #P <
0.05 vs. GN.
deviation expressing as CP = CPtarget − CPGAPDH.
In this quantification method, measured CP is defined
as the point at which the fluorescence rises above the
background fluorescence. Finally, N0 of the target gene
was calculated and relatively compared to the expression
of GAPDH mRNA as housekeeping gene.
Light and immunohistochemistry microscopy
All microscopic examinations were performed in a
blinded fashion. Three lm sections of paraffin-embedded
tissue were stained with periodic acid-Schiff (PAS). In
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Fig. 3. Indices of glomerular mesangial cell
lysis in rats 1 day after induction of acute
anti-thy1 glomerulonephritis (GN) (protocol
1, injury). Shown are glomerular nuclei count
(A) indicating mesangial cell lysis, basal (B),
and lipopolysaccharide (LPS)-stimulated ni-
tric oxide (NO) production (C) as well as in-
ducible nitric oxide synthase (iNOS) mRNA
expression (D). The rats were treated with
the guanylate cyclase stimulator Bay 41-2272
from day 6 before disease induction until sac-
rifice. Anti-thy1 glomerulonephritis was in-
duced by injection of OX-7 antibody. Normal
control animals (control) were injected with
phosphate-buffered saline (PBS). ∗∗P < 0.01
and ∗∗∗P < 0.001 vs. control.
protocol 1, the number of cell nuclei was counted in 15
glomeruli of 80 to 100 lm diameter from each animal for
calculation of mesangial cell lysis [16].
In protocol 2, glomerular matrix expansion was evalu-
ated on PAS-stained slides by rating the percentage of the
mesangial matrix occupying areas in 20 glomeruli from
each rat (0% to 100%) [12]. The number of infiltrating
macrophages was analyzed in 15 glomeruli of each ani-
mal using a primary mouse-anti-ED1 antibody (Serotec,
Hamburg, Germany) and a secondary goat antimouse
antibody coupled with the EnvisionTM staining system
(DakoCytomation, Hamburg, Germany) [15]. Fibrino-
gen deposition was determined with a primary rabbit an-
tifibrinogen antibody and a secondary goat anti-rabbit
antibody coupled with the EnvisionTM staining system
(DakoCytomation). Glomerular fibrinogen deposition is
expressed as the percentage of fibrinogen-positive area
in 15 glomeruli from each rat (0% to 100%) [15].
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). Statistical analysis between the groups was
performed by one-way analysis of variance (ANOVA)
and a subsequent Mann-Whitney U test. A P value < 0.05
was considered significant.
RESULTS
Body weight, bleeding time, blood pressure, and plasma
cGMP levels
In protocols 1 and 2, the animals’ body weights were
not significantly different at the beginning and end of
the experiments. Since results for rat tail bleeding time,
systolic blood pressure, and plasma cGMP levels were
similar in both protocols, they were combined. Rat tail
bleeding time and systemic blood pressure were compa-
rable between normal and disease control rats (bleeding
time 268 ± 22 seconds and 298 ± 36 seconds) (Fig. 1A)
(blood pressure 123 ± 2 mm Hg and 118 ± 2 mm Hg)
(Fig. 1B) (both P = NS). Treatment with Bay 41-2272
prolonged bleeding time (471 ± 41 seconds) (P < 0.01)
and reduced systemic blood pressure (102 ± 3 mm Hg) (P
< 0.01) in comparison to disease controls. Plasma cGMP
levels were significantly higher in the untreated anti-thy1
animals than in the normal controls (4130 ± 650 fmol/mL
vs. 2120 ± 260 fmol/mL) (P < 0.05) and were significantly
further increased by Bay 41-2272 treatment (6610 ±
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Fig. 4. Glomerular mRNA expression of en-
dothelial nitric oxide synthase (eNOS) (A),
a1 soluble guanylate cyclyse (alpha1 sGC)
(B), and b1 soluble guanylate cyclase (beta1
sGC) (C) in rats 1 day after induction of acute
anti-thy1 glomerulonephritis (GN) (proto-
col 1, injury). The rats were treated with
the guanylate cyclase stimulator Bay 41-2272
from day 6 before disease induction until sac-
rifice. Anti-thy1 glomerulonephritis was in-
duced by injection of OX-7 antibody. Normal
control animals (control) were injected with
phosphate-buffered saline (PBS). mRNA was
analyzed by a real-time polymerase chain re-
action (PCR) method using gyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as
housekeeping gene. mRNA expression is
shown as a percentage of the normal control
group. ∗∗∗P < 0.001 vs. control.
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Fig. 5. Basal (A) and nitric oxid-stimulated
(B) glomerular cyclic guanosine monophos-
phate (cGMP) synthesis in rats 1 day
after induction of acute anti-thy1 glomeru-
lonephritis (GN) (protocol 1, injury).
The rats were treated with the guanylate
cyclase stimulator Bay 41-2272 from day
6 before disease induction until sacrifice.
Anti-thy1 glomerulonephritis was induced by
injection of OX-7 antibody. Normal control
animals (control) were injected with
phosphate-buffered saline (PBS). cGMP
generation was measured by enzyme-linked
immunosorbent assay (ELISA) in glomeruli
harvested from individual animals in the
presence or absence of the nitric oxide donor
DEA/NO. ∗∗P < 0.01 vs. control.
810 fmol/mL) (P < 0.05) vs. glomerulonephritis (P < 0.01
vs. control) (Fig. 2). The increase in bleeding time and
plasma cGMP levels and the reduction in blood pressure
caused by Bay 41-2272 document the in vivo bioavailabil-
ity of the drug and are consistent with its cGMP synthesis-
enhancing properties.
Soluble guanylate cyclase in the injury phase of acute
anti-thy1 glomerulonephritis (protocol 1)
Compared to the normal control animals, injection
of anti-thy1 antibody resulted in a significantly reduced
glomerular cell number (43.9 ± 4.6 vs. 56.3 ± 1.1) (P <
0.001) (Fig. 3A) and significant increases in basal (6.9 ±
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Fig. 6. Urinary protein excretion 7 days after induction of acute anti-
thy1 glomerulonephritis (GN) (protocol 2, repair). Treatment with Bay
41-2272 was started 24 hours after disease induction. Urine was collected
for 24 hours using metabolic cages. ∗P < 0.05 vs. GN.
0.5 nmol/mL vs. 2.1 ± 0.3 nmol/mL) (P < 0.001) (Fig.
3B) and LPS-stimulated glomerular nitric oxide produc-
tion (49.1 ± 4.6 nmol/mL vs. 9.3 ± 0.9 vs. nmol/mL) (P <
0.001) (Fig. 3C) and glomerular iNOS mRNA expression
(263 ± 37% vs. 100 ± 37%) (P < 0.01) (Fig. 3D).
The expression and activity of the nitric oxide-cGMP
signaling cascade showed the following picture: In com-
parison to the normal control group, induction of anti-
thy1 glomerulonephritis did not significantly change
eNOS expression (144 ± 23% vs. 100 ± 15%) (P = 0.26)
(Fig. 4A), while expression of the a1 and b1 chain of
the soluble guanylate cyclase was dramatically decreased
(10 ± 2% vs. 100 ± 21% and 13 ± 2% vs. 100 ± 22%,
respectively) (both P < 0.001 vs. control) (Fig. 4B and
4C). Corresponding to the gene expression, basal and
nitric oxide-stimulated glomerular cGMP release was
markedly diminished in the untreated nephritic animals
as compared to the normal controls (basal cGMP re-
lease 10 ± 1 fmol/well vs. 27 ± 5 fmol/well, nitric oxide-
stimulated cGMP release 34 ± 4 fmol/well vs. 143 ±
23 fmol/well) (both P < 0.01 vs. control) (Fig. 5).
Treatment with Bay 41-2272 had no significant influ-
ence on the parameters characterizing disease activity on
day 1 (glomerular cell number 44.3 ± 1.2, basal nitric ox-
ide production 6.9 ± 1.7 nmol/mL, LPS-stimulated nitric
oxide production 50.1 ± 8.8 nmol/mL, and iNOS mRNA
expression 226 ± 26%) (P = NS for all parameters vs.
glomerulonephritis) (Fig. 3). The same was true for the
expression and activity of the glomerular nitric oxide-
cGMP signaling pathway (eNOS mRNA expression 100
± 14%, a1 soluble guanylate cyclase mRNA 6 ± 2%, b1
soluble guanylate cyclase 10 ± 2%, basal cGMP produc-
tion 11 ± 1 fmol/well, and nitric oxide-stimulated cGMP
production 25 ± 3 fmol/well) (P = NS for all parameters
vs. glomerulonephritis) (Figs. 4 and 5).
Together, the results from protocol 1 consistently show
that the expression and activity of the nitric oxide-cGMP
pathway is almost completely disrupted 1 day after in-
duction of anti-thy1 glomerulonephritis. Administration
of Bay 41-2272 was unable to increase glomerular cGMP
production and subsequently had no influence on the de-
gree of mesangial cell injury during this phase of anti-thy1
glomerulonephritis.
Soluble guanylate cyclase in the repair phase of acute
anti-thy1 glomerulonephritis (protocol 2)
Seven days after injection of anti-thy1 antibody,
disease was characterized by significant increases in
proteinuria (165.1 ± 9.5 mg/24 hours) (Fig. 6), histo-
logic matrix accumulation (matrix score 73.2 ± 2.2%),
glomerular production of TGF-b1 (816 ± 66 pg/mL), fi-
bronectin (69,587 ± 2886 ng/mL), and PAI-1 (1368 ±
40 ng/mL) (P <0.01 vs. control for all parameters) (Fig. 7).
As compared to the normal control animals, untreated
nephritic animals showed a slight decrease in eNOS
mRNA expression (72% ± 10%) (P = 0.08 = NS vs.
control) (Fig. 8), while mRNA levels of a1 and b1 sol-
uble guanylate cyclase were markedly increased (562 ±
76% and 330 ± 31%) (both P < 0.001 vs. control). In line
with the mRNA expression data, basal and nitric oxide-
stimulated cGMP synthesis was significantly increased
in the nephritic animals (basal cGMP production 381 ±
155 fmol/well, nitric oxide-stimulated cGMP production
38,011 ± 17,528 fmol/well) (both P < 0.01 vs. control)
(Fig. 9).
In the repair protocol, treatment with Bay 41-2272
significantly decreased proteinuria (110.4 ± 18.3 mg/24
hours (P < 0.05 vs. control) (Fig. 6), histological matrix
accumulation (matrix score 64.8 ± 1.6%) and glomeru-
lar production of TGF-b1 (603 ± 49 pg/mL), fibronectin
(45,668 ± 2513 ng/mL), and PAI-1 (1156 ± 53 ng/mL)
(P < 0.05 vs. glomerulonephritis for all parameters)
(Fig. 7). In comparison to the untreated disease con-
trols, administration of Bay 41-2272 was associated with
marked increases in the expression of the nitric oxide-
cGMP signaling cascade: eNOS mRNA expression 125 ±
19% (P < 0.05 vs. glomerulonephritis) (Fig. 8A), a1
guanylate cyclase mRNA 1750 ± 544% (P < 0.05 vs.
glomerulonephritis) (Fig. 8B), and b1 guanylate cyclase
1217 ± 463% (P < 0.05 vs. glomerulonephritis). While
basal glomerular cGMP production was similar in treated
and untreated nephritic animals (381 ± 155 fmol/well vs.
380 ± 98 fmol/well) (Fig. 9A), glomerular nitric oxide-
stimulated cGMP production was significantly further in-
creased in the Bay 41-2272-treated animals (181,969 ±
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Fig. 7. Markers of glomerular matrix
expansion 7 days after induction of acute
anti-thy1 glomerulonephritis (GN) (protocol
2, repair). Shown are the glomerular matrix
accumulation (A) and glomerular production
of transforming growth factor (TGF)-b1
(B), fibronectin (C), and plaminogen-
activator inhibitor (PAI)-1 (D). Controls
received phosphate-buffered saline (PBS)
(control). Treatment with Bay 41-2272 was
started 24 hours after disease induction.
Matrix expansion was scored on periodic
acid-Schiff (PAS)-stained slides. Glomeruli
were harvested from individual animals and
cultured at a density of 2000 per mL for 48
hours. ∗P < 0.05 and ∗∗P < 0.01 vs. GN.
114,909 fmol/well) (P < 0.05 vs. glomerulonephritis)
(Fig. 9B).
Effect of Bay 41-2272 on glomerular TGF-b1 production
in vitro
As shown in Figure 10, the effect of Bay 41-2272 was
analyzed in cultured glomeruli harvested from normal
and day 7 anti-thy1 nephritic animals. In both groups, in-
creasing concentrations of Bay 41-2272 significantly de-
creased glomerular 48 hours TGF-b1 protein production
in a dose-dependent manner. In normal glomeruli, 0.1, 1,
5, and 10 lmol/L Bay 41-2272 reduced TGF-b1 synthesis
by 16%, 24%, 28%, and 26%, and in nephritic glomeruli,
by 10%, 15%, 25%, and 21%, respectively.
Effect of Bay 41-2272 on glomerular macrophage number
and fibrinogen deposition
In comparison to the normal controls, nephritic ani-
mals at day 7 showed a moderate elevation in glomeru-
lar p-selectin expression (132 ± 20%) (P = NS vs.
control) (Fig. 11A) and a highly significant increase in
glomerular ED1-positive cells (9.2 ± 1.2 vs. 0.8 ± 0.2 cells
per glomerular section) (P < 0.01) (Fig. 11B) and fib-
rinogen deposition (9.8 ± 2.2% vs. 0.4 ± 0.1% staining-
positive area per glomerulus). Treatment with Bay 41-
2272 limited significantly glomerular macrophage infil-
tration (6.2 ± 0.5 cells per glomerular section) (P < 0.05
vs. glomerulonephritis) (Fig. 11B) and fibrinogen depo-
sition (3.8 ± 0.7% staining-positive area per glomerulus)
(P < 0.05 vs. glomerulonephritis). In addition, the mod-
erate increase of glomerular p-selectin expression seen in
the untreated nephritic animals was prevented by Bay 41-
2272 treatment (85 ± 10.2%) (P = NS vs. glomulonephri-
tis) (Fig. 11A).
Taken together, the results of protocol 2 show
that nitric oxide-cGMP signal transduction is markedly
up-regulated during the repair phase of anti-thy1
glomerulonephritis. Treatment with Bay 41-2272 re-
sulted in a further significant increase of soluble guany-
late cyclase expression and activity and limited the
fibrotic response characterizing this phase of anti-thy1
glomerulonephritis.
DISCUSSION
As it is the case in other organs, the nitric oxide-cGMP
signaling cascade is spatially distributed to a high degree
in the renal tissue [4, 21]. Since nitric oxide generally acts
through paracrine diffusion to its target cell rather than by
intracellular signaling, the expression of NOS and soluble
guanylate cyclase differ at the cellular level. Expression
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Fig. 8. mRNA expression of endothelial ni-
tric oxide synthase (eNOS) (A) and a1 sol-
uble guanylate cyclase (alpha1 sGC) (B),
and b1 soluble guanylate cyclyase (beta1
sGC) (C) 7 days after induction of acute
anti-thy1 glomerulonephritis (GN) (proto-
col 2, repair). Treatment with Bay 41-2272
was started 24 hours after disease induc-
tion. Anti-thy1 glomerulonephritis was in-
duced by injection of OX-7 antibody. Normal
control animals (control) were injected with
phosphate-buffered saline (PBS). mRNA was
analyzed by a real-time polymerase chain re-
action (PCR) method using glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as
housekeeping gene. mRNA expression is
shown as a percentage of the normal control
group. ∗∗∗P < 0.001 vs. control; #P < 0.05 vs.
GN.
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Fig. 9. Basal (A) and nitric oxide-stimulated
(B) glomerular cyclic guanosine monophos-
phate (cGMP) synthesis 7 days after induction
of acute anti-thy1 glomerulonephritis (GN)
(protocol 2, repair). Treatment with Bay 41-
2272 was started 24 hours after disease in-
duction. Anti-thy1 glomerulonephritis was in-
duced by injection of OX-7 antibody. Normal
control animals (control) were injected with
phosphate-buffered saline (PBS). cGMP gen-
eration was measured by enzyme-linked im-
munosorbent assay (ELISA) in glomeruli har-
vested from individual animals in the presence
of absence of the nitric oxide donor DEA/NO.
∗∗P < 0.01 and ∗∗∗P < 0.001 vs. control; #P <
0.05 vs. GN.
of soluble guanylate cyclase mRNA and protein has
been demonstrated in mesangial cells of both the intra-
cellular and extracellular mesangium and in podocytes,
but not in glomerular endothelial cells [4, 22]. Outside
the glomerulus, soluble guanylate cyclase has been doc-
umented in cortical and interstitial fibroblasts as well as
along the renal vasculature [4]. The two NOSs that pro-
vide the soluble guanylate cyclase with its main activator
have been shown in close connection to soluble guany-
late cyclase expressing cells [4, 21]. eNOS is exclusively
expressed in endothelial cells and provides the main sig-
nal for soluble guanylate cyclase activation in the vas-
culature and the mesangium. Neuronal NOS (nNOS) is
located in macula densa cells and is closely linked to the
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Fig. 10. Effects of the soluble guanylate cyclyase stimulator Bay 41-
2272 on (A) and nephritic (B) glomerular normal transforming growth
factor (TGF)-b1 production in vitro (protocol 2, repair). Glomeruli were
harvested from individual animals (normal nonnephritic and day 7-
nephritic animals) and cultured at a density of 2000 per mL for 48
hours in the presence of the indicated concentrations of Bay 41-2272.
Glomeruli without Bay 41-2272 served as control. ∗P < 0.05 vs. control.
soluble guanylate cyclase activity in the extraglomerular
mesangium.
The present study shows that expression and activity
of soluble guanylate cyclase is both dramatically and con-
trarily altered during the course of anti-thy1 glomeru-
lonephritis. Shortly after anti-thy1 antibody-induced
mesangial cell injury had occurred, glomerular expres-
sion of a1 and b1 soluble guanylate cyclase was dramat-
ically reduced and the activity of the glomerular soluble
guanylate cyclase as determined as cGMP-production in
exposure to nitric oxide was almost completely abolished.
This contrasted to the subsequent glomerular matrix ex-
pansion phase, in which the glomerular expression of the
soluble guanylate cyclase was strongly upregulated and
the glomerular cGMP response to nitric oxide was man-
ifoldly increased, respectively. This characteristic dual
expression pattern of the glomerular soluble guanylate
cyclase is likely to be explained by the destiny of the
mesangial cell, which is the main glomerular host of
the soluble guanylate cyclase [4] during the course of
anti-thy1 diseases. In the injury phase, the loss of solu-
ble guanylate cyclase expression and activity paralleled
mesangial cell lysis, while during the following repair
phase up-regulation of the soluble guanylate cyclase went
along with mesangial cell expansion and proliferation.
The dramatic down- and up-regulation of soluble
guanylate cyclase activity found in the course of anti-
thy1 glomerulonephritis goes beyond our current un-
derstanding of the regulation of the L-arginine-nitric
oxide-cGMP axis in glomerular disease. Previously, it had
generally been assumed that the activity of this pathway
is mainly depending on the capability of eNOS to gen-
erate nitric oxide [7, 9, 10]. In this sense, impaired re-
nal nitric oxide production has been linked to insufficient
supply with its main precursor L-arginine and the cofactor
tetrahydrobiopterin as well as to increased deactivation
of the nitric oxide produced, for instance, by free radicals
[6, 10, 23]. From this point of view, the term nitric ox-
ide deficiency has been mainly understood as deficiency
in the synthesis of nitric oxide, and soluble guanylate cy-
clase has played a rather passive role. The soluble guany-
late cyclase enzyme has been thought to be expressed
constitutively and to transduce the nitric oxide signal
without further modulation [3]. However, our findings
in acute anti-thy1 glomerulonephritis reveal that soluble
guanylate cyclase can be the object of a marked tran-
scriptional regulation and this has a marked effect on the
subsequent ability of nitric oxide to signal via cGMP. This
conclusion became most evident in the injury protocol.
Despite glomerular nitric oxide production being
markedly increased, glomerular nitric oxide-cGMP sig-
naling was disrupted because of a loss of the soluble
guanylate cyclase enzyme. Although to lesser extent than
in our study, a decrease in the expression or activity
of vascular soluble guanylate cyclase has recently been
reported in several disease models characterized by a
functional nitric oxide deficiency. These models include
spontaneously hypertensive rats, aging, myocardial in-
farction, angiotensin II infusion, lead-induced hyperten-
sion, and diabetic Goto-Kakizate rats [24–29]. In many
of these studies, endothelial nitric oxide production was
found to be normal or even increased as well. Thus,
impaired expression or activity of the soluble guany-
late cyclase enzyme can functionally mimic nitric oxide
deficiency.
In addition to the focus on soluble guanylate cyclase,
the specific pharmacologic soluble guanylate cyclase-
stimulator Bay 41-2272 was used to further character-
ize the role of the nitric oxide-cGMP signaling pathway
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Fig. 11. Glomerular p-selectin mRNA ex-
pression (A) and macrophage infiltration
(B) 7 days after induction of acute anti-
thy1 glomerulonephritis (GN) (protocol 2,
repair). Treatment with Bay 41-2272 was
started 24 hours after disease induction.
Anti-thy1 glomerulonephritis was induced by
injection of OX-7 antibody. Normal con-
trol animals (control) were injected with
phosphate-buffered saline (PBS). P-selectin
mRNA was analyzed by a real-time poly-
merase chain reaction (PCR) method us-
ing glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as housekeeping gene and
is shown as a percentage of the normal con-
trol group. Glomerular macrophage infiltra-
tion is expressed as number of ED1 antibody-
positive cells per glomerular cross-section.
∗P < 0.05 vs. GN.
in anti-thy1 glomerulonephritis. In the injury protocol,
Bay 41-2272 failed to amplify glomerular nitric oxide-
induced cGMP generation, probably because of the loss
of glomerular soluble guanylate cyclase expression. With
this in mind, it is not surprising that Bay 41-2272 had
no effect on the degree of anti-thy1 antibody-induced
mesangial cell injury. In contrast, glomerular nitric oxide-
induced cGMP production was found to be strongly
elevated in the Bay 41-2272-treated animals during the
subsequent repair phase. Although already up-regulated
by the disease itself, the further amplification of glomeru-
lar cGMP generation by Bay 41-2272 significantly limited
the fibrotic response of the repair phase, as shown by re-
ductions in proteinuria, glomerular histologic matrix ac-
cumulation, and expression of TGF-b1, fibronectin, and
PAI-1. Of interest in this context is the finding that solu-
ble guanylate cyclase enhancer treatment not only signif-
icantly increased glomerular nitric oxide-induced cGMP
generation, but also the mRNA expression of both sub-
units of the soluble guanylate cyclase. One could spec-
ulate that this may be a direct effect of Bay 41-2272 on
soluble guanylate cyclase expression, however, it might
as well be just a reflection of the improved glomerular
wound repair in the treatment group.
Bay 41-2272’s antifibrotic effect in anti-thy1 glomeru-
lonephritis expands on the findings of previous investi-
gations in anti-thy1 glomerulonephritis using L-arginine
supplementation or nitric oxide donation [11, 12]. Given
the L-arginine-nitric oxide-cGMP axis, the very simi-
lar beneficial effects on glomerular TGF-b overexpres-
sion achieved by soluble guanylate cyclase enhancement
strongly suggest that L-arginine supplementation and ni-
tric oxide donation mediate its antifibrotic actions via
cGMP signaling. Furthermore, the study suggests that
pharmacologic enhancement of nitric oxide-cGMP sig-
nal transduction may be a reasonable strategy to over-
come limitations of L-arginine supplementation or ni-
tric oxide donation in treating fibrotic renal disease [10,
12, 30].
The antifibrotic effect of Bay 41-2272 in anti-thy1
glomerulonephritis can be related to blood pressure-
dependent and -independent effects of increased cGMP
production. The decrease in blood pressure by Bay 41-
2272 may have played a role, although the fibrotic re-
sponse in anti-thy1 glomerulonephritis is generally not
altered by changes in the blood pressure level [10, 31,
32]. That pressure-independent, cGMP-dependent mech-
anisms were likely operating is suggested by several lines
of evidence. First, the in vitro experiments in which Bay
41-2272 lowered the TGF-b production of cultured nor-
mal and nephritic glomeruli imply that cGMP interacts
directly with the expression of this key fibrosis media-
tor. This finding is in a line with a recent study show-
ing that overexpression of the cGMP-dependent protein
kinase G down-regulates thrombospondin 1 expression
and TGF-b activity in mesangial cells exposed to high
glucose [33]. Second, Bay 41-2272 treatment went along
with significant decreases in glomerular macrophage infil-
tration and platelet deposition. Both can serve as relevant
intraglomerular sources of increased TGF-b expression
and both are known to be regulated by cGMP [14, 15,
17, 34]. Finally, cGMP has been found to inhibit renal
cell proliferation in culture [35]. That this effect may be
involved is suggested by a very recent study demonstrat-
ing that mesangial cell proliferation in anti-thy1 glomeru-
lonephritis is decreased by stimulation of soluble guany-
late cyclase [abstract; Hohenstein et al, J Am Soc Nephrol
14:63A, 2003].
The dual and contrary expression and activity pattern
of soluble guanylate cyclase during anti-thy1 glomeru-
lonephritis may be related the pathologic glomerular cell
changes which are characteristic for this model. Based
on the limiting actions of cGMP on cell proliferation and
matrix production [33, 35, 36], one may speculate that
the loss of soluble guanylate cyclase activity 1 day af-
ter induction of mesangial cell lysis could be related to
the rapid and marked glomerular cell proliferation and
matrix expansion that follows. In our model, glomerular
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TGF-b and matrix protein synthesis peak around day 7
and thereafter decline over weeks until they are back to
normal again. Based on the reestablishment and marked
up-regulation of the soluble guanylate cyclase activity
documented on day 7, one may speculate in turn that
reestablished nitric oxide-cGMP signaling may have con-
tributed to the subsequent resolution of the disease.
CONCLUSION
The present study shows that glomerular nitric ox-
ide signaling via cGMP is markedly impaired during
the injury phase of anti-thy1 glomerulonephritis, while
it is highly up-regulated during subsequent repair. In
the latter phase, further pharmacologic soluble guany-
late cyclase stimulation limits glomerular TGF-b over-
expression and matrix accumulation. The results suggest
that soluble guanylate cyclase represents an important, at
least partially blood pressure-independent, anti-fibrotic
pathway in glomerular disease.
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